^
Association details:
| Biomarker: | IL6 elevation |
|---|---|
| Cancer: | Melanoma |
| Drug: | Opdivo (nivolumab) (PD1 inhibitor) + Yervoy (ipilimumab) (CTLA4 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Serum interleukin-6 and C-reactive protein are associated with survival in melanoma patients receiving immune checkpoint inhibition
Published date:
06/23/2020
Excerpt:
Higher baseline levels of IL-6 and the N/L ratio, and to a lesser degree, CRP were associated with shorter survival in patients receiving ICI or chemotherapy....For patients treated with ipilimumab combined with nivolumab, IL-6 was associated with poor OS with an adjusted HR of 3.08 (95% CI 1.84 to 5.16) (univariate HR of 3.68, 95% CI 2.21 to 6.12)…
DOI:
10.1136/jitc-2020-000842
Source:
Title:
Final clinical results and first translational correlates of a phase 2 trial of adaptively dosed nivolumab and ipilimumab based on early radiographic assessment in advanced melanoma (ADAPT-IT).
Published date:
05/25/2023
Excerpt:
ADAPT-IT was a multicenter, phase 2 clinical trial with a planned sample size of 60 patients with unresectable melanoma. Patients received two doses of nivo (1 mg/kg) + ipi (3 mg/kg) followed by a computed tomography scan at week 6....Higher baseline IL-6 was observed in non-responders compared to responders (p = 0.03; n = 26) and was associated with shorter PFS (HR for progression or death 1.24; 95% CI: 1.01-1.52; p = 0.04).
DOI:
10.1200/JCO.2023.41.16_suppl.9517
Trial ID:
Test:
